TRV130 - Mu opioid Biased Ligand for Acute Pain
| Program (Target) | Indication | Phase |
| TRV027 (AT1R) | Acute Heart Failure |  - Phase 2 |
| TRV130 (MOR) | Post-Operative Pain |  - Phase 1 |
| TRV734 (MOR) | Moderate-to-Severe Pain |  - Preclinical |
| Delta Opioid | Pain, Parkinson's disease |  - Lead Optimization |
| Kappa Opioid | Neuropathic Pain | - Lead Optimization |
TRV130 is an intravenous G protein biased ligand that targets the mu opioid receptor. Trevena is developing TRV130 for the treatment of moderate-to-severe acute pain where intravenous therapy is needed, with a clinical development focus in acute postoperative pain.
Copyright © Trevena, Inc.